High-sensitivity versus conventional troponin in the emergency department for the diagnosis of acute myocardial infarction
© Freund et al.; licensee BioMed Central Ltd. 2011
Received: 1 February 2011
Accepted: 10 June 2011
Published: 10 June 2011
Recently, newer assays for cardiac troponin (cTn) have been developed which are able to detect changes in concentration of the biomarker at or below the 99th percentile for a normal population. The objective of this study was to compare the diagnostic performance of a new high-sensitivity troponin T (HsTnT) assay to that of conventional cTnI for the diagnosis of acute myocardial infarction (AMI) according to pretest probability (PTP).
In consecutive patients who presented to our emergency departments with chest pain suggestive of AMI, levels of HsTnT were measured at presentation, blinded to the emergency physicians, who were asked to estimate the empirical PTP of AMI. The discharge diagnosis was adjudicated by two independent experts on the basis of all available data.
A total of 317 patients were included, comprising 149 (47%) who were considered to have low PTP, 109 (34%) who were considered to have moderate PTP and 59 (19%) who were considered to have high PTP. AMI was confirmed in 45 patients (14%), 22 (9%) of whom were considered to have low to moderate PTP and 23 (39%) of whom were considered to have high PTP (P < 0.001). In the low to moderate PTP group, HsTnT levels ≥ 0.014 μg/L identified AMI with a higher sensitivity than cTnI (91%, 95% confidence interval (95% CI) 79 to 100, vs. 77% (95% CI 60 to 95); P = 0.001), but the negative predictive value was not different (99% (95% CI 98 to 100) vs. 98% (95% CI 96 to 100)). There was no difference in area under the receiver operating characteristic (ROC) curve between HsTnT and cTnI (0.93 (95% CI 0.90 to 0.98) vs. 0.94 (95% CI 0.88 to 0.97), respectively).
In patients with low to moderate PTP of AMI, HsTnT is slightly more useful than cTnI. Our results confirm that the use of HsTnT has a higher sensitivity than conventional cTnI.
Early detection of acute myocardial infarction (AMI) remains a major concern, with approximately 15 million patients per year presenting to US emergency departments (EDs) with symptoms suggestive of the diagnosis [1, 2]. Among such patients, a strong association between elevated cardiac troponin (cTn) levels and myocardial necrosis has been clearly demonstrated [3–5]. Conventional cTn has revolutionised the management of patients presenting with suspected acute coronary syndrome (ACS), including risk stratification of ACS, and the use of cTn measurements is recommended by current guidelines . A cutoff point at the 99th percentile has been endorsed, as values above this level have repeatedly proven to be associated with adverse cardiovascular outcomes, including death [7–13]. However, the delay (4 to 6 hours, and 12 hours for peak level) in its elevation remains of concern, since it can delay AMI diagnosis and its treatment and increases the burden on EDs. Thus, cTn measurement does not reliably exclude AMI without repeated negative measurements over the course of 4 to 6 hours. These last years, newer assays have been developed, and High Sensitivity Troponin (HsTn) has been associated with higher sensitivity and NPV than conventional cTn. Recent studies have shown excellent diagnostic performance, even with early presentation to the ED , and a better diagnostic accuracy than cTn . However, the latter studies did not evaluate the diagnostic accuracy of high-sensitivity troponin T (HsTnT) according to the pretest probability (PTP) of AMI. For example, ST elevation on an electrocardiogram of a patient with chest pain would be diagnosed as AMI, and then the patient would undergo cardiac catheterization without any measurement of a cardiac biomarker. Furthermore, one of the potential strengths of HsTnT might be the exclusion of AMI earlier than it would be with conventional cTn measurement as suggested by previous studies . Therefore, the objectives of the current study were to confirm whether HsTnT is more sensitive than conventional cTnI to detect AMI according to the patient's PTP.
Materials and methods
During the period from August 2005 to January 2007 in three urban teaching hospitals, we prospectively enrolled consecutive hospital outpatients (> 18 years of age) who presented to the ED with chest pain suggestive of ACS with the onset or peak occurring within the previous 6 hours. Patients with acute or chronic kidney failure requiring dialysis were excluded. The study was performed according to the principles of the Declaration of Helsinki and approved by the local ethics committee (Comité de Protection des Personnes Ile-de-France VI, CHU Pitié-Salpétrière Hospital, Paris, France). Because routine medical care was unchanged, waiver of informed consent was authorised. We followed most of the recommendations concerning the reporting of diagnostic studies set forth by the Standards for Reporting of Diagnostic Accuracy initiative .
As part of the routine assessment in our institutions, all patients underwent an initial clinical evaluation that included clinical history, a physical examination, 12-lead electrocardiography (ECG), pulse oximetry, routine blood tests and chest X-rays. After these routine tests were done, and before cardiac biomarker results were available, ED physicians were asked to offer an 'empirical' clinical probability of AMI (low, medium or high PTP) based on cardiovascular risk factors, type of chest pain, physical findings and electrocardiogram abnormalities [17, 18]. Conventional cardiac troponin I (cTnI) was measured at presentation and, if needed, was repeated after 3 to 9 hours as long as it was clinically indicated. Thus, according to the diagnosis of non-ST elevation MI (NSTEMI) or ST elevation MI (STEMI), the patients were admitted either to the cardiology unit for further evaluation and treatment or directly to the catheterization laboratory for primary percutaneous coronary intervention. However, the timing and treatment of patients were left to the discretion of the attending physicians according to the suspected diagnosis. ED physicians in charge were blinded to the results of HsTnT, and biologists were blinded to the emergency diagnosis suspected by physicians.
To determine the etiologic diagnosis of chest pain at presentation for each patient, two independent experts (ED physicians) who were blinded to the results of HsTnT reviewed all available medical records (including patient history, physical findings, results of laboratory and radiologic testing, ECG, echocardiography, cardiac exercise test, coronary angiography and summary chart at discharge) pertaining to the patient from the time of ED presentation to 30-day follow-up. In the event of diagnostic disagreement, cases were reviewed and adjudicated in conjunction with a third expert (also an ED physician).
AMI was diagnosed according to the joint European Society of Cardiology/American College of Cardiology/American Heart Association/World Heart Federation Task Force redefinition of MI guidelines . Diagnosis of AMI required a cTnI increase above the 10% coefficient of variation (CV) value associated with at least one of the following: symptoms of ischaemia, new ST-T changes or a new Q wave on an electrocardiogram, imaging of new loss of viable myocardium or normal cTnI on admission. Unstable angina was diagnosed in patients with constant normal cTnI levels and a history or clinical symptoms consistent with ACS. Predefined further diagnostic categories included AMI (STEMI with the presence of ST-segment elevation in at least two continuous leads on ECG, new onset of left bundle branch block or NSTEMI), unstable angina, and a third group including cardiac but not coronary symptoms (for example, stable angina, myocarditis, arrhythmias and heart failure), noncardiac symptoms (for example, pulmonary embolism) and chest pain of unknown origin.
To assess the influence of renal function on cTn measurement accuracy, the creatinine level was measured in each patient and then renal function was estimated using the Modification of Diet in Renal Disease study equation .
In two EDs (Cochin Hospital and La Pitié Salpêtrière Hospital, Paris, France), plasmatic cTnI concentrations were routinely measured on an Xpand HM analyzer using the Cardiac Troponin I one-step enzyme immunoassay system (Siemens Healthcare Diagnostics Inc., Newark, NJ, USA). The measurement range extended from 0.04 to 40.00 μg/L. The threshold for this method (0.14 μg/L) corresponds to the lowest substrate concentration that can be reproducibly measured with a CV ≤ 10%. In the remaining ED (Bicêtre Hospital, Le Kremlin-Bicêtre, France), plasmatic cTnI concentrations were routinely measured on an Access analyser (Beckman Coulter, Inc., Brea, CA, USA). The measurement range of this one-step chemiluminescence immunoassay extends from 0.01 to 100.00 μg/L. The threshold (10% CV) given by the manufacturer is 0.06 μg/L.
Heparinised samples collected upon admission and, if available, samples collected 3 to 9 hours later were analysed. Plasmatic highly sensitive cardiac TnT (HScTnT) concentrations were measured using the HScTnT one-step electrochemiluminescence immunoassay on an Elecsys 2010 analyzer (Roche Diagnostics, Meylan, France). The measuring range extended from 0.003 to 10 μg/L. The threshold for this method is 0.014 μg/L and corresponds to the 99th percentile. The CV was found to be < 10% at 0.014 μg/L. In our laboratory, CVs obtained in Roche Diagnostics quality controls containing 0.027 and 2.360 μg/L of HScTnT were < 4%. These analytical performance levels were in accordance with data provided by the manufacturer.
Contingency data according to pretest probabilitya
Low to moderate PTP
All hypothesis testing was two-tailed, and P < 0.05 was considered statistically significant. Statistical analysis was performed using StatView for Windows version 5.0 software (SAS Institute, Cary, NC, USA) and MedCalc software for ROC analysis (MedCalc Software, Mariarkerke, Belgium). Graphs were built with GraphPad Prism 5 software (GraphPad Software Inc., La Jolla, CA, USA).
Baseline characteristics of the population according to the pretest probabilitya
Low or moderate PTP
Number of patients
57 ± 17
56 ± 17
60 ± 17
Systolic BP, mmHg
141 ± 28
141 ± 27
144 ± 30
Diastolic BP, mmHg
80 ± 16
80 ± 16
82 ± 16
Heart rate, beats/minute
85 ± 45
84 ± 23
80 ± 19
Pulse oxymetry, %
97 ± 3
97 ± 3
97 ± 2
TIMI risk score
1 (0 to 3)
1 (0 to 2)
2 (1 to 4)
Family history of CAD
Personal history of CAD
History of heart failure
Typical thoracic pain
Positive cTnI at admission
eGFR, mL/minute/1.73 m2
77 (62 to 94)
77 (64 to 94)
76 (56 to 91)
Treatment within first 24 hours after admission
Admission to CCU
HsTnT diagnostic performances
Diagnostic accuracy of HScTnT compared to that of cTnI for the diagnosis of AMI according to pretest probabilitya
All patients (N = 317)
97 (94 to 98)
78 (62 to 89)
95 (92 to 97)
93 (90 to 96)
21.5 (20.1 to 22.9)
0.32 (0.23 to 0.36)
93 (89 to 100)*
82 (77 to 87)*
47 (36 to 58)*
99 (96 to 100)
84 (79 to 88)*
5.3 (4.8 to 5.8)
0.08 (0.04 to 0.12)
Low to moderate PTP group (n = 258)
77 (54 to 92)
97 (94 to 99)
71 (49 to 87)
98 (95 to 99)
95 (92 to 97)
26.1 (24.0 to 28.1)
0.23 (0.17 to 0.30)
91 (69 to 98)
85 (79 to 89)*
36 (24 to 49)**
99 (96 to 100)
85 (80 to 89)*
6.0 (5.3 to 6.6)
0.11 (0.06 to 0.15)
High PTP group (n = 59)
65 (43 to 83)
94 (79 to 99)
88 (62 to 98)
81 (65 to 91)*
83 (71 to 91)**
11.7 (10.1 to 13.4)
0.37 (0.18 to 0.55)
96 (76 to 100)***
67 (49 to 81)***
65 (47 to 81)
96 (78 to 100)
78 (65 to 87)
2.9 (2.3 to 3.4)
0.07 (0 to 0.17)
Net reclassification improvement
Table 3 shows patient classification on the basis of using cTnI or HsTnT to diagnose AMI and highlights the shifts between the two classifications.
Influence of renal function on cTn performances
During the past two decades, cTn has been adopted as the preferred biomarker for the diagnosis of acute MI, a position reaffirmed in recent consensus guidelines [14, 22]. However, until recently, cTn methods were unable to deliver the requisite analytic performance at the 99th percentile, an extremely low cutoff point within the range of analytic 'noise' in most conventional assays. The present prospective multicenter study of unselected patients who presented to the ED with chest pain of < 6 hours' duration produced major different findings about the new HsTnT assay.
First, the sensitivity of the HsTnT assay remains high at all PTP levels. The excellent sensitivity of 93% was comparable to that found in a previous study (84% to 90% ) and significantly higher than conventional cTn (69% in our study and 72% previously described ). However, despite its good sensitivity of 91% in the low and moderate PTP groups, the use of HsTnT assays would not allow physicians to rule out AMI in these patients with a unique measurement of HsTnT, as the NPV is not quite perfect, that is, a unique value < 0.014 μg/L cannot avoid a second blood test several hours later to control HsTnT level. It should be noted that in the high PTP group, HsTnT showed excellent diagnostic accuracy, with 93% sensitivity (compared to 80% for cTnI) and 96% NPV (compared to 93% for cTnI). Recently, Januzzi et al.  showed that HsTnT was able to detect ACS more sensitively than a corresponding conventional cTnT method in a population of low to moderate PTP patients with chest pain.
Second, we confirmed the value of 0.014 μg/L as an optimal threshold [14, 22]. We confirmed the high diagnostic accuracy of HsTnT; the AUC of HsTnT was 0.93, similar to that found by investigators in previous studies. Thus, Keller et al.  and Reichlin et al.  found AUCs that ranged from 0.94 to 0.96. However, and conversely to other reports, our findings do not show a better AUC for HsTnT than for conventional cTnI measurements. Several reasons could explain this discrepancy.
First, we used cTnI (from Siemens and Beckman Coulter) instead of cTnT as the comparator, thus with a different assay than was previously used, and our comparator cTnI could have slightly better analytical qualities than the one called the 'standard assay' that was used in the Reichlin et al. study . Second, in our study, the AUC for cTnI, or 'conventional troponin', that is, the comparator, was 0.94 (95% CI, 0.90 to 0.98), which in fact is included in the 95% CIs of the AUCs of other comparators previously used. For example, Christ et al.  found an AUC of the standard fourth-generation cTnT assay, that is, its comparator, of 0.89 (95% CI, 0.81 to 0.98). Unfortunately, Keller et al.  did not detail the 95% CIs of their AUCs for cTn, and Reichlin et al.  used an old standard assay which in fact underestimated the diagnostic performance of the cTn assay. Other reasons could explain this discrepancy in the AUC of ROC curves for cTnI. Our inclusion criteria differ from those of Reichlin et al. , Keller et al.  and others who included patients with chest pain of less than 12 hours' duration with high rates of AMI and unstable angina. Our population markedly differs from those in previous studies. Thus, other conventional cTnT assays (also called third-generation cTnTs, from Roche Diagnostics) that could be used in studies as comparators for HSTnT have been reported to have excellent AUCs. Collinson et al.  found that at 6 hours postpain, the AUC of cTnT was 0.989 (95% CI, 0.966 to 1.0). However, although the comparison of AUCs remains the most popular metric by which to capture discrimination, it appears that for models containing clinical risk and possessing reasonably good discrimination, very important associations between the biomarker and the end point are required to provide significantly different AUCs. In other words, comparisons of AUCs might be considered powerless in identifying biomarkers of interest in such situations . To address this problem, new ways of evaluating the usefulness of biomarkers have been described, but they are used very rarely in studies evaluating diagnostic tests or biomarkers [14, 22]. In the present study, reclassification, for example, NRI, demonstrated that the use of HsTnT with a clinical assessment (including ECG findings) only slightly improved the discriminative power and performance in predicting AMI [14, 22, 25]. As described in previous studies, we have demonstrated a worsening of specificity and lower PPV of HsTnT measurement compared to those of conventional cTn; that is, we observed an increase in false-positive findings. Last, the present study is the first to investigate the impact of kidney function on HsTnT levels. We found no significant difference in the AUCs of HsTnT regarding eGFR tertiles. Only in tertile 1 was the optimal threshold value of HsTnT increased (0.036 μg/ml compared to 0.014 μg/L).
Conventional cTn is widely used and is recommended for the management of patients presenting with suspected ACS . However, the delay in detecting its elevation prevents early, safe discharge from the ED without repeated negative measurements during the course of 4 to 6 hours. Recent studies have shown excellent diagnostic performance of HsTnT measurement, even with early presentation to the ED , and better diagnostic accuracy than cTn . Despite its higher sensitivity, we did not find that HsTnT had better NPV, diagnostic accuracy or AUC, conversely to the findings of previous studies . Furthermore, as expected, specificity and PPV were lower. The clinical setting, time of inclusion, rate of AMI in our patient population and our focus on low or moderate PTP of AMI could explain this discrepancy.
The emergency medicine field would greatly benefit from a new biomarker that eases and hastens the triage of noncardiac chest pain patients. The main incremental value that could have provided a new highly sensitive assay for Tn would have allowed emergency physicians to rule out AMI and discharge patients with a normal Tn value. This study suggests that even when considering only low to moderate PTP patients, the better sensitivity of HsTnT cannot translate into a real clinical improvement. A NPV of 99% can be interpreted as excellent, but this slight gain from that of cTnI is not sufficient to change the conventional method of chest pain investigation in our ED, even in low to moderate PTP patients. This subgroup is the one of most interest in our study, as high PTP patients (and even more so for STEMI patients) are not to be promptly discharged and will more easily undergo further investigations and care.
To rapidly and reliably rule out AMI, the answer may be assessment of a combination of different biomarkers, as suggested by Reichlin et al.  in their study, where they found that with a copeptin level < 14 pmol/L and a TnT level < 0.01 μg/L, AMI was excluded with 99.7% NPV in an unselected population of chest pain patients.
The main limitation of our study is the small sample of patients, especially patients with AMI. We cannot exclude the possibility that better results might have been found with a larger sample. Our sample is comparable to those used in previous studies, however, and most of all, we believe that the imperfect NPV that we describe herein is the major result of our study, which could not have been corrected by including more patients.
Our study has some other limitations. First, we performed only a single measurement of HsTnT. We did not evaluate its kinetics, which would have been interesting, especially in the 'grey zone' (between 0.014 μg/L and 0.050 μg/L). A second value could have provided more data, as previously described in the Giannitsis et al. study , which reported that a doubling in the HsTnT concentration within 3 hours of chest pain (with first negative HsTnT and no electrocardiogram abnormality) was associated with a 100% PPV of a diagnosis of NSTEMI.
Second, we used empirical PTP and not a standardised, validated one [17, 18]. However, outcomes in the low and moderate PTP population (only nine with confirmed NSTEMI), and differences in clinical characteristics at admission suggested that even though empirical, this evaluation by the clinician was accurate. Furthermore, one of the strengths of our study was that it evaluated differences in diagnostic performance for the HsTnT regarding PTP as demonstrated for D-dimers and empirical suspicion of pulmonary embolism . Another limitation of our study is that different conventional Tn assays have been used at the two study sites with different threshold values and CVs. These assays were used because they were both local and well-understood methods at the time of the study.
Third, we used two different assays for the comparator (that is, conventional TnI): a Siemens cTnI assay in two centres (CCH and PSL) and a Beckman Coulter assay in the third centre (BCT). The ROC curve for the cTnI is, then, a combined ROC curve of two different assays, making it imprecise. However, the two different ROC curves (for each assay) have similar AUCs.
Last, this study was underpowered to find any significant change in the detection of AMI in the low to moderate PTP patients. However, as the NPV is not perfect in our patient population, we expect that this would remain the case with a larger sample.
We have confirmed that HsTnT is accurate for diagnosis of AMI, with a sensitivity slightly higher than that of conventional cTnI, regardless of PTP of AMI in patients with chest pain presenting to an ED. However, we did not show a better NPV. Intervention studies are clearly warranted to support the use of HsTnT to help ED physicians achieve clinical improvement in treating patients with chest pain and providing them with an early, safe discharge from the hospital.
Fast and reliable detection of ACS remains a great concern in the ED.
Novel assays for troponin have been developed and tested recently.
HsTnT is more sensitive than cTn.
In this study, the weak gains realised by measuring HsTnT rather than cTn in terms of NPV is not sufficient to change daily clinical practice.
acute coronary syndrome
acute myocardial infarction
area under the curve
coefficient of variation
negative predictive value
net reclassification improvement
non-ST elevation myocardial infarction
positive predictive value
receiver operating characteristic
ST elevation myocardial infarction.
We thank Roche Diagnostics France (Meylan, France) for providing free reagents and kits for HsTnT assays. The tests and kits for the HsTnT assays were provided free of charge by Roche Diagnostics France. Other sources of support were provided solely from departmental sources.
We also thank Dr DJ Baker (Department of Anaesthesiology, CHU Necker-Enfants Malades, Assistance Publique des Hôpitaux de Paris (AP-HP), Paris, France) for reviewing the manuscript. This study was partially presented at the research forum of the 2010 scientific assembly of the American College of Emergency Physicians, Las Vegas, NV, USA, 29 September 2010.
- Task Force for Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of European Society of Cardiology, Bassand JP, Hamm CW, Ardissino D, Boersma E, Budaj A, Fernández-Avilés F, Fox KA, Hasdai D, Ohman EM, Wallentin L, Wijns W: Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J. 2007, 28: 1598-1660.View ArticleGoogle Scholar
- Nawar EW, Niska RW, Xu J: National Hospital Ambulatory Medical Care Survey: 2005 emergency department summary. Adv Data. 2007, 386: 1-32.PubMedGoogle Scholar
- Hamm CW, Ravkilde J, Gerhardt W, Jørgensen P, Peheim E, Ljungdahl L, Goldmann B, Katus HA: The prognostic value of serum troponin T in unstable angina. N Engl J Med. 1992, 327: 146-150. 10.1056/NEJM199207163270302.View ArticlePubMedGoogle Scholar
- Lindahl B, Toss H, Siegbahn A, Venge P, Wallentin L, for the FRISC Study Group: Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. N Engl J Med. 2000, 343: 1139-1147. 10.1056/NEJM200010193431602.View ArticlePubMedGoogle Scholar
- Antman EM, Tanasijevic MJ, Thompson B, Schactman M, McCabe CH, Cannon CP, Fischer GA, Fung AY, Thompson C, Wybenga D, Braunwald E: Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med. 1996, 335: 1342-1349. 10.1056/NEJM199610313351802.View ArticlePubMedGoogle Scholar
- Thygesen K, Alpert JS, White HD, Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction: Universal definition of myocardial infarction. J Am Coll Cardiol. 2007, 50: 2173-2195. 10.1016/j.jacc.2007.09.011.View ArticlePubMedGoogle Scholar
- Eggers KM, Jaffe AS, Lind L, Venge P, Lindahl B: Value of cardiac troponin I cutoff concentrations below the 99th percentile for clinical decision-making. Clin Chem. 2009, 55: 85-92.View ArticlePubMedGoogle Scholar
- Apple FS, Pearce LA, Smith SW, Kaczmarek JM, Murakami MM: Role of monitoring changes in sensitive cardiac troponin I assay results for early diagnosis of myocardial infarction and prediction of risk of adverse events. Clin Chem. 2009, 55: 930-937. 10.1373/clinchem.2008.114728.View ArticlePubMedGoogle Scholar
- Apple FS, Smith SW, Pearce LA, Ler R, Murakami MM: Use of the Centaur TnI-Ultra assay for detection of myocardial infarction and adverse events in patients presenting with symptoms suggestive of acute coronary syndrome. Clin Chem. 2008, 54: 723-728. 10.1373/clinchem.2007.097162.View ArticlePubMedGoogle Scholar
- Eggers KM, Lagerqvist B, Venge P, Wallentin L, Lindahl B: Persistent cardiac troponin I elevation in stabilized patients after an episode of acute coronary syndrome predicts long-term mortality. Circulation. 2007, 116: 1907-1914. 10.1161/CIRCULATIONAHA.107.708529.View ArticlePubMedGoogle Scholar
- James SK, Lindahl B, Armstrong P, Califf R, Simoons ML, Venge P, Wallentin L: A rapid troponin I assay is not optimal for determination of troponin status and prediction of subsequent cardiac events at suspicion of unstable coronary syndromes. Int J Cardiol. 2004, 93: 113-120. 10.1016/S0167-5273(03)00157-8.View ArticlePubMedGoogle Scholar
- Venge P, Lagerqvist B, Diderholm E, Lindahl B, Wallentin L: Clinical performance of three cardiac troponin assays in patients with unstable coronary artery disease (a FRISC II substudy). Am J Cardiol. 2002, 89: 1035-1041. 10.1016/S0002-9149(02)02271-3.View ArticlePubMedGoogle Scholar
- Morrow DA, Cannon CP, Rifai N, Frey MJ, Vicari R, Lakkis N, Robertson DH, Hille DA, DeLucca PT, DiBattiste PM, Demopoulos LA, Weintraub WS, Braunwald E: Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: results from a randomized trial. JAMA. 2001, 286: 2405-2412. 10.1001/jama.286.19.2405.View ArticlePubMedGoogle Scholar
- Reichlin T, Hochholzer W, Bassetti S, Steuer S, Stelzig C, Hartwiger S, Biedert S, Schaub N, Buerge C, Potocki M, Noveanu M, Breidthardt T, Twerenbold R, Winkler K, Bingisser R, Mueller C: Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. N Engl J Med. 2009, 361: 858-867. 10.1056/NEJMoa0900428.View ArticlePubMedGoogle Scholar
- Januzzi JL, Bamberg F, Lee H, Truong QA, Nichols JH, Karakas M, Mohammed AA, Schlett CL, Nagurney JT, Hoffmann U, Koenig W: High-sensitivity troponin T concentrations in acute chest pain patients evaluated with cardiac computed tomography. Circulation. 2010, 121: 1227-1234. 10.1161/CIRCULATIONAHA.109.893826.PubMed CentralView ArticlePubMedGoogle Scholar
- Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, Moher D, Rennie D, de Vet HC, Lijmer JG, Standards for Reporting of Diagnostic Accuracy: The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Ann Intern Med. 2003, 138: W1-W12.View ArticlePubMedGoogle Scholar
- Chandra A, Lindsell CJ, Limkakeng A, Diercks DB, Hoekstra JW, Hollander JE, Kirk JD, Peacock WF, Gibler WB, Pollack CV, EMCREG i*trACS Investigators: Emergency physician high pretest probability for acute coronary syndrome correlates with adverse cardiovascular outcomes. Acad Emerg Med. 2009, 16: 740-748. 10.1111/j.1553-2712.2009.00470.x.View ArticlePubMedGoogle Scholar
- Pollack CV, Braunwald E: 2007 update to the ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: implications for emergency department practice. Ann Emerg Med. 2008, 51: 591-606. 10.1016/j.annemergmed.2007.09.004.View ArticlePubMedGoogle Scholar
- Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D: A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999, 130: 461-470.View ArticlePubMedGoogle Scholar
- Ray P, Le Manach Y, Riou B, Houle TT: Statistical evaluation of a biomarker. Anesthesiology. 2010, 112: 1023-1040. 10.1097/ALN.0b013e3181d47604.View ArticlePubMedGoogle Scholar
- Pencina MJ, D'Agostino RB, D'Agostino RB, Vasan RS: Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2008, 27: 157-172. 10.1002/sim.2929. discussion 207-112View ArticlePubMedGoogle Scholar
- Keller T, Zeller T, Peetz D, Tzikas S, Roth A, Czyz E, Bickel C, Baldus S, Warnholtz A, Fröhlich M, Sinning CR, Eleftheriadis MS, Wild PS, Schnabel RB, Lubos E, Jachmann N, Genth-Zotz S, Post F, Nicaud V, Tiret L, Lackner KJ, Münzel TF, Blankenberg S: Sensitive troponin I assay in early diagnosis of acute myocardial infarction. N Engl J Med. 2009, 361: 868-877. 10.1056/NEJMoa0903515.View ArticlePubMedGoogle Scholar
- Christ M, Popp S, Pohlmann H, Poravas M, Umarov D, Bach R, Bertsch T: Implementation of high sensitivity cardiac troponin T measurement in the emergency department. Am J Med. 2010, 123: 1134-1142. 10.1016/j.amjmed.2010.07.015.View ArticlePubMedGoogle Scholar
- Collinson PO, Gaze DC, Morris F, Morris B, Price A, Goodacre S: Comparison of biomarker strategies for rapid rule out of myocardial infarction in the emergency department using ACC/ESC diagnostic criteria. Ann Clin Biochem. 2006, 43: 273-280. 10.1258/000456306777695555.View ArticlePubMedGoogle Scholar
- Levinson SS: Clinical validation of biomarkers for predicting risk. Adv Clin Chem. 2009, 48: 1-25.View ArticlePubMedGoogle Scholar
- Reichlin T, Hochholzer W, Stelzig C, Laule K, Freidank H, Morgenthaler NG, Bergmann A, Potocki M, Noveanu M, Breidthardt T, Christ A, Boldanova T, Merki R, Schaub N, Bingisser R, Christ M, Mueller C: Incremental value of copeptin for rapid rule out of acute myocardial infarction. J Am Coll Cardiol. 2009, 54: 60-68. 10.1016/j.jacc.2009.01.076.View ArticlePubMedGoogle Scholar
- Giannitsis E, Becker M, Kurz K, Hess G, Zdunek D, Katus HA: High-sensitivity cardiac troponin T for early prediction of evolving non-ST-segment elevation myocardial infarction in patients with suspected acute coronary syndrome and negative troponin results on admission. Clin Chem. 2010, 56: 642-650. 10.1373/clinchem.2009.134460.View ArticlePubMedGoogle Scholar
- Carrier M, Righini M, Djurabi RK, Huisman MV, Perrier A, Wells PS, Rodger M, Wuillemin WA, Le Gal G: VIDAS D-dimer in combination with clinical pre-test probability to rule out pulmonary embolism: a systematic review of management outcome studies. Thromb Haemost. 2009, 101: 886-892.PubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.